Dermatitis News

Safety data for ruxolitinib cream, a Janus kinase inhibitor, in the first year after its approval has shown that the drug is generally well tolerated for the treatment of atopic dermatitis or vitiligo, according to a postmarketing review.

The FDA has accepted Dermavant Science’s supplemental new drug application for Vtama cream 1% for the treatment of atopic dermatitis in adults and children aged 2 years and older, the company announced in a press release.

Healio has compiled April’s most-read news in dermatology.

Dupilumab demonstrated sustained effectiveness across patientreported outcome measures in adult and pediatric individuals with atopic dermatitis, according to a study.

Adults and adolescents with moderate to severe atopic dermatitis treated with upadacitinib reported year-long improvements in skin symptoms, mental health and quality of life, according to a study.

A new study finds that dupilumab is associated with an increased risk for cutaneous T-cell lymphoma in patients taking the drug for atopic dermatitis.

Healio has compiled March’s most-read news in dermatology.

SAN DIEGO — In this Healio video perspective from the American Academy of Dermatology Annual Meeting, Alphyn Biologics CEO Neal Koller discusses new data from the company’s phase 2a trial of AB-101a for the treatment of atopic dermatitis.

SAN DIEGO — Researchers found that children with moderate to severe atopic dermatitis have a higher mean weight and BMI, but a lower mean height, than healthy children, according to a poster presented here.

SAN DIEGO — Ruxolitinib cream improved quality of life outcomes, including sleep and itch, in children aged 2 to 11 years with atopic dermatitis, according to a poster presented at the American Academy of Dermatology Annual Meeting.